Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation

Seung Jin Lee; Ji Hea Kim; Ka Won Kang; Byung Hyun Lee; Byung Soo Kim

doi:10.1016/j.scr.2020.102030

Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation

Seung Jin Lee, Ji Hea Kim, Ka Won Kang, Byung Hyun Lee, Byung Soo Kim

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a hematological cancer characterized by an uncontrolled proliferation of antibody-secreting plasma cells within the bone marrow. Currently, cell therapy such as chimeric antigen receptor T-cell (CAR-T) based on induced pluripotent stem cells (iPSCs) has received attention for treating MM. However, the generation of iPSCs from MM patients appears to be very rarely reported. Here we generated an iPSC line from CD34+ bone marrow cells of a patient with MM using human placenta-derived cell conditioned medium (hPCCM), offering a relatively high efficiency in humanized conditions. This iPSC line might be a useful model for research on MM.

Original language	English
Article number	102030
Journal	Stem Cell Research
Volume	49
DOIs	https://doi.org/10.1016/j.scr.2020.102030
Publication status	Published - 2020 Dec

ASJC Scopus subject areas

Developmental Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.scr.2020.102030

Cite this

@article{3b5a7c6e636048519df6b6eaae84b9fa,

title = "Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation",

abstract = "Multiple myeloma (MM) is a hematological cancer characterized by an uncontrolled proliferation of antibody-secreting plasma cells within the bone marrow. Currently, cell therapy such as chimeric antigen receptor T-cell (CAR-T) based on induced pluripotent stem cells (iPSCs) has received attention for treating MM. However, the generation of iPSCs from MM patients appears to be very rarely reported. Here we generated an iPSC line from CD34+ bone marrow cells of a patient with MM using human placenta-derived cell conditioned medium (hPCCM), offering a relatively high efficiency in humanized conditions. This iPSC line might be a useful model for research on MM.",

author = "Lee, {Seung Jin} and Kim, {Ji Hea} and Kang, {Ka Won} and Lee, {Byung Hyun} and Kim, {Byung Soo}",

note = "Funding Information: This study was funded by the Bio & Medical Technology Development Program of the National Research Foundation, which is funded by the Ministry of Science & ICT [ 2017M3A9C8060403 ]. Funding Information: This study was funded by the Bio & Medical Technology Development Program of the National Research Foundation, which is funded by the Ministry of Science & ICT [2017M3A9C8060403]. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = dec,

doi = "10.1016/j.scr.2020.102030",

language = "English",

volume = "49",

journal = "Stem Cell Research",

issn = "1873-5061",

publisher = "Elsevier",

}

TY - JOUR

T1 - Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation

AU - Lee, Seung Jin

AU - Kim, Ji Hea

AU - Kang, Ka Won

AU - Lee, Byung Hyun

AU - Kim, Byung Soo

N1 - Funding Information: This study was funded by the Bio & Medical Technology Development Program of the National Research Foundation, which is funded by the Ministry of Science & ICT [ 2017M3A9C8060403 ]. Funding Information: This study was funded by the Bio & Medical Technology Development Program of the National Research Foundation, which is funded by the Ministry of Science & ICT [2017M3A9C8060403]. Publisher Copyright: © 2020 The Author(s)

PY - 2020/12

Y1 - 2020/12

N2 - Multiple myeloma (MM) is a hematological cancer characterized by an uncontrolled proliferation of antibody-secreting plasma cells within the bone marrow. Currently, cell therapy such as chimeric antigen receptor T-cell (CAR-T) based on induced pluripotent stem cells (iPSCs) has received attention for treating MM. However, the generation of iPSCs from MM patients appears to be very rarely reported. Here we generated an iPSC line from CD34+ bone marrow cells of a patient with MM using human placenta-derived cell conditioned medium (hPCCM), offering a relatively high efficiency in humanized conditions. This iPSC line might be a useful model for research on MM.

AB - Multiple myeloma (MM) is a hematological cancer characterized by an uncontrolled proliferation of antibody-secreting plasma cells within the bone marrow. Currently, cell therapy such as chimeric antigen receptor T-cell (CAR-T) based on induced pluripotent stem cells (iPSCs) has received attention for treating MM. However, the generation of iPSCs from MM patients appears to be very rarely reported. Here we generated an iPSC line from CD34+ bone marrow cells of a patient with MM using human placenta-derived cell conditioned medium (hPCCM), offering a relatively high efficiency in humanized conditions. This iPSC line might be a useful model for research on MM.

UR - http://www.scopus.com/inward/record.url?scp=85094583906&partnerID=8YFLogxK

U2 - 10.1016/j.scr.2020.102030

DO - 10.1016/j.scr.2020.102030

M3 - Article

C2 - 33142253

AN - SCOPUS:85094583906

SN - 1873-5061

VL - 49

JO - Stem Cell Research

JF - Stem Cell Research

M1 - 102030

ER -

Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this